LZIC antibody (AA 31-130) (Cy5)
Quick Overview for LZIC antibody (AA 31-130) (Cy5) (ABIN1410346)
Target
See all LZIC AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 31-130
-
Cross-Reactivity
- Mouse
-
Predicted Reactivity
- Human,Rat,Dog,Cow,Sheep,Pig,Horse,Chicken,Rabbit
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human LZIC
-
Isotype
- IgG
-
-
-
-
Application Notes
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Expiry Date
- 12 months
-
-
- LZIC (Leucine Zipper and CTNNBIP1 Domain Containing (LZIC))
-
Alternative Name
- LZIC
-
Background
-
Synonyms: Leucine zipper and CTNNBIP1 domain containing protein, Leucine zipper and ICAT homologous domain containing protein, leucine zipper domain and ICAT homologous domain containing, LZIC antibodyprotein LZIC, LZIC_HUMAN.
Background: LZIC is a 190 amino acid protein that belongs to the CTNNBIP1 family. Ubiquitously expressed, LZIC is found at highest levels in kidney and is upregulated in a few gastric carcinomas. The gene encoding LZIC maps to human chromosome 1, which spans 260 million base pairs, contains over 3,000 genes and comprises nearly 8 % of the human genome. Chromosome 1 houses a large number of disease-associated genes, including those that are involved in familial adenomatous polyposis, Stickler syndrome, Parkinson?s disease, Gaucher disease, schizophrenia and Usher syndrome. Aberrations in chromosome 1 are found in a variety of cancers, including head and neck cancer, malignant melanoma and multiple myeloma.
Target
-